Compare YDES & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YDES | PCRX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | YDES | PCRX |
|---|---|---|
| Price | $11.97 | $25.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.86 |
| AVG Volume (30 Days) | 110.9K | ★ 656.9K |
| Earning Date | 09-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $510,360.00 | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | ★ N/A | $54.59 |
| Revenue Growth | ★ 45.76 | 3.14 |
| 52 Week Low | $5.30 | $18.17 |
| 52 Week High | $31.00 | $27.64 |
| Indicator | YDES | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 69.20 |
| Support Level | N/A | $23.63 |
| Resistance Level | N/A | $24.81 |
| Average True Range (ATR) | 0.00 | 0.92 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 0.00 | 85.75 |
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.